[go: up one dir, main page]

WO2010149172A3 - SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. - Google Patents

SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. Download PDF

Info

Publication number
WO2010149172A3
WO2010149172A3 PCT/DK2010/050163 DK2010050163W WO2010149172A3 WO 2010149172 A3 WO2010149172 A3 WO 2010149172A3 DK 2010050163 W DK2010050163 W DK 2010050163W WO 2010149172 A3 WO2010149172 A3 WO 2010149172A3
Authority
WO
WIPO (PCT)
Prior art keywords
adrenergic
combination
clotting factors
sympathicomimetics
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2010/050163
Other languages
French (fr)
Other versions
WO2010149172A2 (en
Inventor
Pär JOHANSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of WO2010149172A2 publication Critical patent/WO2010149172A2/en
Publication of WO2010149172A3 publication Critical patent/WO2010149172A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel use and methods of treatment using the combination of clotting factors and sympathicomimetic / adrenergic receptor agonists with pro-hemostatic activity. Administration of a combination of clotting factors and sympathicomimetic / adrenergic receptor agonists increases blood clot strength as visualized by TEG analyses. The compounds of the invention are particularly useful in the treatment of trauma patients.
PCT/DK2010/050163 2009-06-24 2010-06-24 SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. Ceased WO2010149172A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200970036 2009-06-24
DKPA200970036 2009-06-24

Publications (2)

Publication Number Publication Date
WO2010149172A2 WO2010149172A2 (en) 2010-12-29
WO2010149172A3 true WO2010149172A3 (en) 2011-04-07

Family

ID=42470515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2010/050163 Ceased WO2010149172A2 (en) 2009-06-24 2010-06-24 SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.

Country Status (1)

Country Link
WO (1) WO2010149172A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066700A2 (en) * 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225160A2 (en) * 1985-11-26 1987-06-10 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
GB2216803A (en) * 1988-03-23 1989-10-18 Colgate Palmolive Co Dental floss and picks
WO2008127654A2 (en) * 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
WO2009043355A2 (en) * 2007-10-02 2009-04-09 Johansson Paer SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2458978A2 (en) 1979-06-07 1981-01-02 Commissariat Energie Atomique METHOD AND DEVICE FOR INTERCONNECTING ELECTRONIC COMPONENTS
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
CA2739933A1 (en) 2000-02-11 2001-08-16 Bayer Healthcare Llc Factor vii or viia-like molecules
JP2003531682A (en) 2000-04-28 2003-10-28 フジオメッド インコーポレイテッド Hemostatic compositions of polyacids and polyalkylene oxides and methods of using the same
RU2373282C2 (en) 2003-06-19 2009-11-20 Байер Хелткэр Ллк VERSIONS OF GLA DOMAIN OF FACTOR VII OR VIIa
US8152750B2 (en) 2003-09-12 2012-04-10 Marine Polymer Technologies, Inc. Vascular access preservation in hemodialysis patients
DE10361306A1 (en) 2003-12-24 2005-07-28 Lts Lohmann Therapie-Systeme Ag Wound dressing and wound dressing with a vasoconstrictive ingredient, and manufacturing method therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0225160A2 (en) * 1985-11-26 1987-06-10 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
GB2216803A (en) * 1988-03-23 1989-10-18 Colgate Palmolive Co Dental floss and picks
WO2008127654A2 (en) * 2007-04-11 2008-10-23 The University Of North Carolina At Chapel Hill Methods and compositions for intra-articular coagulation proteins
WO2009043355A2 (en) * 2007-10-02 2009-04-09 Johansson Paer SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH

Also Published As

Publication number Publication date
WO2010149172A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2012003418A3 (en) Functionally selective ligands of dopamine d2 receptors
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
AU2018253580A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
PH12013502294A1 (en) Fgfr1 agonists and methods of use
EA201071169A1 (en) HYDROXYMETHYLPYRROLIDINES AS AGONISTS OF β3 ADRENERGIC RECEPTORS
WO2009105534A3 (en) Ophthalmic nsaids as adjuvants
WO2012142372A3 (en) Compositions and methods for the treatment of nasal conditions
WO2011133879A3 (en) Combination therapies with mitochondrial-targeted anti-tumor agents
WO2007146959A3 (en) Pan-cell surface receptor- specific therapeutics
EA201001253A1 (en) N, N-DESIGNED AMINOALKYLBIPHENYLES AS ANTAGONISTS OF PROSTAGLANDIN RECEPTORS D
AU2011234398A8 (en) Novel NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
EP2291415A4 (en) CATALYSTS FOR THE PREPARATION OF CIS-1,4-POLYDIENES
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2008057930A3 (en) Methods of treating neuropathic pain with retinoic acid receptor agonists
MX2010007490A (en) Preparation of sulfamide derivatives.
TN2015000244A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA108494C2 (en) USES OF (RS)-S-CYCROPROPYL-S-(4-{$4-{$(1R,2R)-2-HYDROXY-1-METHYLPROPYL]OXY}-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}PHENYL ) SULFOXIMIDE FOR THE TREATMENT OF TUMORS
WO2012138223A3 (en) Compounds and methods for altering activin receptor-like kinase signalling
WO2013016278A3 (en) Modulators of antiviral signaling pathways and therapeutic uses thereof
WO2010149172A3 (en) SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
WO2013138338A3 (en) Methods for treating tissue damage associated with ischemia with apoliporotein d
EA201490938A1 (en) SPIROTHYENE-PYRANIPIPERIDINE DERIVATIVES AS ANTAGONISTS OF ORL-1 RECEPTOR FOR USE TO TREAT ALCOHOL DEPENDENCE AND ABUSE OF ALCOHOL
WO2011067711A3 (en) Novel heparanase splice variant
WO2010132208A3 (en) Diagnostic methods for liver disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730696

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 10730696

Country of ref document: EP

Kind code of ref document: A2